These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26378638)

  • 41. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    Xu X; Nan Y
    J Hepatol; 2022 Feb; 76(2):484-485. PubMed ID: 34774637
    [No Abstract]   [Full Text] [Related]  

  • 42. Pathological features of fatty liver disease.
    Yeh MM; Brunt EM
    Gastroenterology; 2014 Oct; 147(4):754-64. PubMed ID: 25109884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prevalence of nonalcoholic fatty liver disease in young patients with abdominal obesity and hypertension].
    Chulkov VS; Sumerkina VA; Abramovskikh OS; Chulkov VS
    Eksp Klin Gastroenterol; 2014; (11):42-5. PubMed ID: 25842663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A REVIEW OF INTERNATIONAL AND NATIONAL CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT-OF NONALCOHOLIC FATTY LIVER DISEASE.
    Golovanova EV; Lazebnik LB
    Eksp Klin Gastroenterol; 2016; (11):76-83. PubMed ID: 29889450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence-Based Medicine and the Problem of Healthy Volunteers.
    Marchesini G; Marchignoli F; Petta S
    Ann Hepatol; 2017 November-December,; 16(6):832-834. PubMed ID: 29055914
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between psoriasis and non-alcoholic fatty liver disease - Updated systematic review and adjusted meta-analysis.
    Phan K; Onggo J; Charlton O; Smith SD
    Australas J Dermatol; 2019 Nov; 60(4):e352-e355. PubMed ID: 30906989
    [No Abstract]   [Full Text] [Related]  

  • 47. [Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease].
    Shi YW; Xiao QQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):915-917. PubMed ID: 33256275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liver involvement in pediatric celiac disease.
    Anania C; De Luca E; De Castro G; Chiesa C; Pacifico L
    World J Gastroenterol; 2015 May; 21(19):5813-22. PubMed ID: 26019445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
    Vanni E; Marengo A; Mezzabotta L; Bugianesi E
    Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [[Current approaches to diagnosing and treating nonalcoholic fatty liver disease].
    Drapkina OM; Deeva TA; Volkova NP; Ivashkin VT
    Ter Arkh; 2014; 86(10):116-23. PubMed ID: 25509904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Interview with PD Dr. Anton Gillessen, Münster. Non-alcoholic fatty liver: change in the life style!].
    Gillessen A
    MMW Fortschr Med; 2015 Jan; 157(1):69. PubMed ID: 25767868
    [No Abstract]   [Full Text] [Related]  

  • 52. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men.
    Ozturk K; Uygun A; Guler AK; Demirci H; Ozdemir C; Cakir M; Sakin YS; Turker T; Sari S; Demirbas S; Karslıoğlu Y; Saglam M
    Atherosclerosis; 2015 Jun; 240(2):380-6. PubMed ID: 25875390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges.
    Cholankeril G; Perumpail RB; Pham EA; Ahmed A; Harrison SA
    Hepatology; 2016 Sep; 64(3):954. PubMed ID: 27388553
    [No Abstract]   [Full Text] [Related]  

  • 55. Testing for Nonalcoholic Fatty Liver Disease.
    Juo YY; Livingston EH
    JAMA; 2019 Nov; 322(18):1836. PubMed ID: 31714988
    [No Abstract]   [Full Text] [Related]  

  • 56. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.
    Lonardo A; Ballestri S; Marchesini G; Angulo P; Loria P
    Dig Liver Dis; 2015 Mar; 47(3):181-90. PubMed ID: 25739820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Non-alcoholic fatty liver diseases].
    Roeb E; Steffen HM; Bojunga J
    Dtsch Med Wochenschr; 2015 Dec; 140(24):1846. PubMed ID: 26625237
    [No Abstract]   [Full Text] [Related]  

  • 58. Transaminases and Pediatric Nonalcoholic Fatty Liver Disease Diagnosis.
    Vajro P
    J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e114. PubMed ID: 29064931
    [No Abstract]   [Full Text] [Related]  

  • 59. Headway and hurdles in non-alcoholic fatty liver disease.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):93. PubMed ID: 31928993
    [No Abstract]   [Full Text] [Related]  

  • 60. [How to deal with increased liver markers].
    Rust C; Gerbes A
    MMW Fortschr Med; 2017 Nov; 159(19):68-70. PubMed ID: 29124577
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.